Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Rubius Therapeutics, Inc. (RUBY)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 |
| | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | | | | | | |
| Selling, general and administrative [+] | 1.1 | 7.3 | 9.9 | 12.6 | 13.9 | 12.0 | 13.9 | 13.2 |
| General and administrative | 1.1 | 7.3 | 9.9 | 12.6 | 13.9 | 12.0 | 13.9 | 13.2 |
| Research and development | 0.9 | 24.2 | 33.0 | 38.3 | 39.8 | 38.0 | 36.1 | 27.7 |
| EBITDA [+] | -1.5 | -28.9 | -41.3 | -49.3 | -50.3 | -48.7 | -48.4 | -39.4 |
| EBITDA growth | -97.0% | -40.8% | -14.7% | 25.1% | 28.4% | 26.3% | 34.8% | -16.2% |
| EBITDA margin | | | | | | | | |
| Depreciation and amortization | 0.4 | 2.7 | 1.6 | 1.6 | 3.4 | 1.3 | 1.5 | 1.5 |
| EBIT [+] | -2.0 | -31.5 | -42.9 | -50.9 | -53.7 | -50.0 | -49.9 | -40.9 |
| EBIT growth | -96.4% | -37.0% | -14.1% | 24.3% | 35.3% | 24.5% | 32.4% | -16.2% |
| EBIT margin | | | | | | | | |
| Non-recurring items | 21.1 | 30.1 | | | | | | |
| Interest expense, net [+] | 1.0 | 1.3 | 1.4 | 1.6 | 1.6 | 1.7 | 1.3 | 1.7 |
| Interest expense | 1.1 | 1.7 | 1.6 | 1.6 | 1.7 | 1.7 | 1.3 | 1.7 |
| Interest income | 0.1 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | 4.0 | 0.1 | 0.0 | 0.0 | 0.4 | 2.7 | 1.0 | 0.3 |
| Other | 1.7 | 0.1 | 0.0 | 0.0 | 0.4 | 2.7 | 1.0 | 0.3 |
| Pre-tax income | -20.1 | -62.9 | -44.2 | -52.4 | -55.0 | -49.0 | -50.2 | -42.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -20.1 | -62.9 | -44.2 | -52.4 | -55.0 | -49.0 | -50.2 | -42.3 |
| Net margin | | | | | | | | |
| |
| Basic EPS [+] | ($0.22) | ($0.70) | ($0.49) | ($0.58) | ($0.63) | ($0.55) | ($0.56) | ($0.51) |
| Growth | -64.4% | 27.5% | -12.6% | 13.1% | 24.4% | 7.9% | 19.2% | -14.9% |
| Diluted EPS [+] | ($0.22) | ($0.70) | ($0.49) | ($0.58) | ($0.63) | ($0.55) | ($0.56) | ($0.51) |
| Growth | -64.4% | 27.5% | -12.6% | 13.1% | 24.4% | 7.9% | 19.2% | -14.9% |
| |
| Shares outstanding (basic) [+] | 90.3 | 90.4 | 90.3 | 90.1 | 88.0 | 89.8 | 89.5 | 82.3 |
| Growth | 2.7% | 0.6% | 0.8% | 9.5% | 9.1% | 11.2% | 11.2% | 2.5% |
| Shares outstanding (diluted) [+] | 90.3 | 90.4 | 90.3 | 90.1 | 88.0 | 89.8 | 89.5 | 82.3 |
| Growth | 2.7% | 0.6% | 0.8% | 9.5% | 9.1% | 11.2% | 11.2% | 2.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|